Aqtual, a Hayward, CA-based precision drugs firm offering an energetic chromatin cell-free DNA (cfDNA) platform, raised $31M in Sequence B funding.
Backers included Daring Capital, Daring Longevity Development Fund, Genoa Ventures, Manta Ray Ventures, Yu Galaxy and others.
The corporate intends to make use of the funds to increase operations and R&D efforts.
Aqtual is a precision drugs firm creating merchandise for persistent illness administration and oncology utilizing a brand new cell-free DNA-based platform, which evaluates protein regulation, epigenetics, and transcriptomics solely utilizing cell-free DNA fragments discovered within the blood. It permits real-time evaluation of illness and therapy whereas overcoming the constraints of earlier cell-free DNA methodologies.
Itts proprietary method permits high-fidelity quantification of tissue-specific gene regulation straight from blood via built-in profiling of illness, microenvironment, and systemic immune response.
FinSMEs
10/07/2025
